Predictive and personalized medicine of pancreatic cancer – CancerProfile
The CancerProfile multidisciplinary project brings together highly complementary translational research institutes to develop a novel standard of patient stratification for predictive and personalized medicine of pancreatic adenocarcinoma cancer. The overall objective is to fully integrate cutting-edge AI-augmented anatomopathology, genomics, and tissue/liquid biopsy analysis in conjunction with functional drug response of tumors, to derive biomarkers indicative of a predictive treatment choice. We will apply an innovative Personalized Functional Profiling (PFP) proprietary technology consisting of direct large-scale analysis of the sensitivity of 3D-printed spheroids derived from patient biopsies in response to a panel of EMA and FDA approved anti-cancer chemotherapeutics. Overall, the objective is to clinically validate new prognostic markers and identify alternative treatment options for tumors resistant to standard chemotherapies.
Project coordination
Benoit Gallix (Institut hospitalo-universitaire de chirurgie mini-invasive guidée par l'image)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partner
LIH Luxembourg Institute of Health / Department of Oncology
LLTech Aquyre Biosciences
IHU Strasbourg Institut hospitalo-universitaire de chirurgie mini-invasive guidée par l'image
Laboratoire National de Santé / Département de Pathologie
Help of the ANR 747,465 euros
Beginning and duration of the scientific project:
October 2021
- 48 Months
